Remember to consider your priors with any stated risk.
Also note that these inexpensive chip based genotyping have about 1% coverage, which may or may not hit the right location for multiple-allele traits and expression is not completely known.
23and me is selling a product, pharmacogenetic information can be an additional bit of information but they should only be a reason to consider getting a second opinion.
Many well known alleles will not ever be fully detected with genome-wide genotyping chips due to the required deletions and sequence similarities. Sure you can get lucky and get a result that will lead you to consult with a health provider but in general these services are for entertainment only.
We have to wait a while before pharmacogenetic testing that is more medically valid will approach these prices and really that will require a technology beyond genome-wide genotyping chips, which are what allowed this low cost service in the first place.
As an example, consider that full sequencing of yDNA costs $500+ and takes much longer to test, yet this is one out of “23”. The Illumina Global Screening Array Chip that 23andme uses for newer tests will always be a compromise and have limitations based on it’s intended purpose, which is to reduce costs as much as possible. Actual medical pharmacogenetic tests will be more targeted or use more specific chips and targeted searches for most conditions.